Bioventus (BVS) Gains from Investment Securities (2020 - 2026)

Bioventus has reported Gains from Investment Securities for 6 years, with the latest figure at $1.0 million in Q1 2026.

• For the quarter ending Q1 2026, Gains from Investment Securities changed N/A year-over-year to $1.0 million; the trailing twelve-month figure through Mar 2026 stood at $1.0 million (down 7.45% YoY), and the FY2025 full-year result was $9000.0, down 99.37% from the prior year.
• Gains from Investment Securities for Q1 2026 stood at $1.0 million, up from $345000.0 in the prior quarter.
• The five-year high for Gains from Investment Securities was $1.0 million in Q1 2026, with the low at -$98000.0 in Q3 2023.
• Historically, Gains from Investment Securities has averaged $329846.2 across 4 years, with a median of $287000.0 in 2023.
• Annual changes were most pronounced in 2023 — Gains from Investment Securities tumbled 135.25% — and 2024, when it surged 592.86%.
• Bioventus' Gains from Investment Securities stood at $282000.0 in 2022, then grew by 2.84% to $290000.0 in 2023, then climbed by 18.97% to $345000.0 in 2024, then soared by 202.61% to $1.0 million in 2026.
• The last three Gains from Investment Securities figures came in at $1.0 million (Q1 2026), $345000.0 (Q4 2024), and $483000.0 (Q3 2024), per Business Quant data.